Fiji Integrated Therapy (FIT) - Triple Therapy for Lymphatic Filariasis, Scabies and Soil Transmitted Helminths in Fiji

Scabies Clinical Trial

— FIT  

Official title:

Community Based Safety Study of 2-drug (Diethylcarbamazine and Albendazole) Versus 3-drug (Ivermectin, Diethylcarbamazine and Albendazole) Therapy for Lymphatic Filariasis, Scabies and Soil Transmitted Helminths in Fiji

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03177993
• Other study ID #: 201607068-2
• Status: Completed
• Phase: N/A
• Start date: July 13, 2017
• Est. completion date: October 24, 2019

Study information

• Verified date: December 2020
• Source: Washington University School of Medicine
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Lymphatic Filariasis (LF), scabies and soil transmitted helminths (STH) are common neglected tropical diseases affecting the people of Fiji. There is a dedicated LF eradication program supported by the World Health Organization (WHO), however scabies and STH are currently managed on an individual level with symptomatic treatment as required. In an attempt to reduce the prevalence of LF globally, research is being undertaken into alternative, more effective treatment options. A recent study in Papua New Guinea demonstrated a new triple drug therapy (ivermectin, diethylcarbamazine and albendazole) is superior to the currently recommended two drug therapy (diethylcarbamazine and albendazole) used by WHO LF programs in the Pacific. However, adverse events were more frequent. Despite no serious adverse events being observed, it is necessary to conduct further studies to review the safety of this new triple therapy before it can be endorsed as an effective mass drug administration (MDA) regimen for LF in endemic countries. Fiji's burden of LF, that has been recalcitrant to previous MDA with diethylcarbamazine and albendazole, make it an ideal site to obtain further efficacy and safety data of the triple therapy. Ivermectin given to communities as MDA has been proven to be effective in reducing the community prevalence of scabies. What is not known is the effects of one dose versus two doses of ivermectin as MDA. This question will be reviewed within the design of the community randomized study. The prevalence of impetigo in a community is linked to scabies and this will also be reviewed. Ivermectin and albendazole are both effective individually against STH. The effectiveness of this combination of treatment as MDA in Fiji for STH has not been studied. The effectiveness for the individual in the short-term and the community in the longer-term will be reviewed. In addition, the acceptability and feasibility of the new therapy in communities at risk of these three diseases will be reviewed.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 4773
• Est. completion date: October 24, 2019
• Est. primary completion date: November 22, 2017
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• All community members that have given written informed consent to participate

Exclusion Criteria:

• No informed consent

Related Conditions & MeSH terms

• Filariasis
• Impetigo
• Lymphatic Filariases
• Scabies
• Soil Transmitted Helminths

Intervention

Drug:
• 3 drug dose - IDA
Lymphatic Filariasis Mass Drug Administration (MDA) with triple drug therapy of ivermectin, diethylcarbamazine, and albendazole (IDA). Participants excluded from ivermectin will receive a topical dose of permethrin cream. Exclusion criteria for ivermectin, diethylcarbamazine and albendazole: severe illness (chronic renal insufficiency, severe chronic liver disease, or any illness that is severe enough to interfere with activities of daily living); allergy to ivermectin, diethylcarbamazine or albendazole; pregnant; breastfeeding within 7 days of delivery; less than 2 years old; OR less than 15 kg In addition if less than 5 years old excluded from ivermectin. Exclusion criteria for permethrin: allergy to permethrin crusted scabies
• 3 drug dose - IDA with second dose of ivermectin
Lymphatic Filariasis Mass Drug Administration (MDA) with triple drug therapy of ivermectin, diethylcarbamazine, and albendazole (IDA). Eight days after treatment participants will be given a second dose of ivermectin alone. Participants excluded from ivermectin will receive a topical dose of permethrin cream both on day 0 and day 8. Exclusion criteria for ivermectin, diethylcarbamazine and albendazole: severe illness (chronic renal insufficiency, severe chronic liver disease, or any illness that is severe enough to interfere with activities of daily living); allergy to ivermectin, diethylcarbamazine or albendazole; pregnant; breastfeeding within 7 days of delivery; less than 2 years old; OR less than 15 kg In addition if less than 5 years old excluded from ivermectin. Exclusion criteria for permethrin: allergy to permethrin crusted scabies
• 2 drug dose - DA
Lymphatic Filariasis Mass Drug Administration (MDA) with the currently used standard of care combination drug therapy of diethylcarbamazine, and albendazole (DA). If scabies is present in the participant or a household member permethrin cream will be provided 8 days after dose of DA. Exclusion criteria for diethylcarbamazine and albendazole: severe illness (chronic renal insufficiency, severe chronic liver disease, or any illness that is severe enough to interfere with activities of daily living); allergy to diethylcarbamazine or albendazole; pregnant; breastfeeding within 7 days of delivery; less than 2 years old; OR less than 15 kg Exclusion criteria for permethrin: allergy to permethrin crusted scabies

Locations

Country	Name	City	State
Fiji	Ministry of Health and Medical Services	Suva

Sponsors (3)

Lead Sponsor	Collaborator
Washington University School of Medicine	Murdoch Children's Research Institute, The Task Force for Global Health

Country where clinical trial is conducted

Fiji, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Frequency, type, and severity of adverse events reported by participants following treatment with triple drug therapy (IDA) and standard two drug therapy (DA) in LF infected and uninfected individuals in a community as measured by CTCAE v4.03	Participants will be interviewed and asked to report their general health status at baseline before receiving treatment and daily for the 2 days following treatment (Active Adverse Event Monitoring phase). For 3 to 7 days following treatment, anyone unwell the preceding day will be actively followed, other participants will be interviewed only if they feel unwell and present to the study team (Passive Adverse Event Monitoring phase).; At any stage if they describe being unwell, further questions to determine type and severity of symptom(s) experienced will be asked and recorded according to pre-defined adverse event table. If participants report moderate to severe symptoms they will have further medical assessments as required.; LF infection status will be determined by Filiarial Test Strip (FTS) and microfilariae (mf) smears.	within 7 days of drug administration
Secondary	Clearance of microfilariae (mf) and filarial antigenemia following treatment with IDA or DA in LF infected individuals as measured by microfilaria count in 60ul thick blood smears and filarial test strip rapid diagnostic antigen test.	Methods of assessment: FTS and Dried Blood Spot (DBS) for filarial antigenemia, mf smears for microfilariae	Baseline and 12 months
Secondary	Prevalence of scabies in study population measured at baseline and 12 months after treatment using the WHO Integrated Management of Childhood Illness (IMCI) skin algorithm	Methods of assessment: Skin examination	Baseline and 12 months
Secondary	Prevalence of STH (hookworm, ascaris, trichuris and strongyloides) as measured by Kato-katz or PCR at baseline and 12 months after treatment	Methods of assessment: Stool samples will be analysed using Kato-katz method, as well as PCR.	Stool collected at baseline (pre-treatment), 4 weeks (individual response), and 12 months (community prevalence).
Secondary	Acceptability and feasibility of IDA and DA in communities at risk of LF, scabies and STH as assessed by survey and focus group discussions.	Methods of assessment: Acceptability Survey, designed specifically for the Triple therapy studies, Focus group discussions, Interviews with key informants	Approximately 4 weeks following treatment
Secondary	Prevalence of impetigo measured at baseline and 12 months after treatment using the WHO Integrated Management of Childhood Illness (IMCI) skin algorithm	Methods of assessment: Skin examination	Baseline and 12 months